RESEARCH Open Access

Safety and efficacy of an olive oil-based triple-chamber bag for parenteral nutrition: a prospective, randomized, multi-center clinical trial in China

Zhen-Yi Jia1, Jun Yang1, Yang Xia1, Da-Nian Tong1, Gary P. Zaloga2, Huan-Long Qin3,4* and OliClinomel N4 Study Group

Abstract

Background: Small studies suggest differences in efficacy and safety exist between olive oil-based (OLIVE) and soybean oil-based (SOYBEAN) parenteral nutrition regimens in hospitalized adult patients. This large, prospective, randomized (1:1), open-label, multi-center, noninferiority study compared the delivery, efficacy, and safety of OLIVE (N = 226) with SOYBEAN (N = 232) in Chinese adults (≥18 years) admitted to a surgical service for whom parenteral nutrition was required.

Methods: Treatments were administered for a minimum of 5 days up to 14 days (to achieve approximately 25 kcal/kg/day, 0.9 g/kg/day amino acids, 0.8 g/kg/day lipid). Impact of treatment on anabolic/catabolic and serum inflammatory, chemistry, and hematological markers, safety, and ease of use were assessed. The primary efficacy variable was serum prealbumin level at Day 5.

Results: OLIVE (n = 219) was not inferior to SOYBEAN (n = 224) based on the prealbumin least square geometric mean [LSGM] ratio [95% CI] 1.12 [1.06, 1.19]; P = 0.002), improved the anabolic/catabolic status of patients enrolled in the study, and was well tolerated compared with SOYBEAN. Improved anabolic status was supported by significantly higher levels of prealbumin at Day 5, albumin at Day 5 and IGF-1 at Day 14 in the OLIVE group, while catabolism was similar between groups. C-reactive protein, intercellular adhesion molecule-1, procalcitonin, and oxidative stress were similar in each group, but infections were significantly lower with OLIVE (3.6 % versus 10.4 %; P < 0.01).

Conclusions: OLIVE provided effective nutrition, was well tolerated, was associated with fewer infections, and conferred greater ease-of-use than SOYBEAN.

Trial registration: NTC 01579097.

Keywords: Infection, Nutritional outcomes, Olive oil-based lipid, Parenteral nutrition, Soy bean oil-based lipid, Surgery

Background

The beneficial effects of parenteral nutrition (PN) in ill patients unable to tolerate adequate enteral feeding are well established [1–3]. PN not only improves nutritional status in malnourished patients, it also reduces complications [4, 5] such as infections, need for mechanical ventilation, and muscle weakness. As a result, PN is an important therapeutic modality for treating patients with compromised intestinal function.

Animal and human studies suggest that the lipid source in PN, and more specifically the fatty-acid composition of the lipid source, may contribute to the risk of complications [6–9]. Such complications include inflammation, oxidation, immune compromise, infections, hyperglycemia, and liver dysfunction/failure. Soybean oil-based lipid emulsions are composed of long-chain triglycerides, primarily linoleic acid (ω-6 polyunsaturated fatty acids [PUFAs]). In contrast, olive oil-based lipid...
emulsions are composed of long-chain triglycerides, primarily oleic acid (ω-9 monounsaturated fatty acids [MUFAs]) [10]. According to the 2012 American Society for Parenteral and Enteral Nutrition (ASPEN) Novel Nutrient Task Force, lipid sources such as safflower oil and soybean oil are considered pro-inflammatory, while olive oil is considered immune neutral [10]. Experimental reports suggest that ω-6 PUFA-rich lipid emulsions that are derived from soybean oil may exaggerate the inflammatory response associated with stress and trauma via activation of the arachidonic acid eicosanoid pathway and have direct effects on lymphocyte, macrophage, and neutrophil functions [11–14]. These ω-6 PUFA effects upon inflammation and immune cell functions may increase the rate of infections. As a result, lipid emulsions with lower linoleic acid levels (ie, olive oil predominant emulsions) have been developed. However, there are limited data to suggest that the replacement of soybean oil-based ω-6 PUFAs with olive oil-based ω-9 MUFAs improves the safety of PN [15, 16]. Therefore, one of the objectives of this study was to evaluate the incidence of infections using two different lipid emulsions that varied in the content of linoleic acid.

In this study, we utilized two different PN regimens differing in lipid emulsion type (olive oil based versus soybean oil based) and delivery system (compounded versus a ready-to-use, three-chamber bag). The primary endpoint chosen was prealbumin level (an index of anabolic and inflammatory status). Due to the lower ω-6 PUFA content (a pro-inflammatory fatty acid) and higher oleic acid content (MUFA with lower oxidation risk) of the olive-oil based lipid emulsion, we hypothesized that this emulsion would be associated with improved anabolic/catabolic status. Anabolism was assessed using prealbumin, albumin, and insulin growth factor-1 (IGF-1) levels. Catabolism was assessed using the protein breakdown end-products of urea and 3-methylhistidine. We also assessed inflammation (interleukin-6 [IL-6], C-reactive protein [CRP], intercellular adhesion molecule-1 [ICAM-1]) and oxidation (malondialdehyde, F2-isoprostanes) biomarkers. By measuring anabolic, catabolic, and inflammatory parameters, we were able to compare changes in anabolic parameters in patients with similar inflammatory and catabolic status. In addition to these nutritional parameters, we assessed clinical outcomes using infections (a marker of immune status), hospital length of stay, mortality, and adverse events. Safety was assessed by measuring biomarkers of organ functions (liver, renal, hematologic, and endocrine). Because a ready-to-use formulation is immediately available to clinicians (no need to compound), we also assessed preparation time.

Although several small studies have investigated the differences between soybean oil-based and olive oil-based lipid emulsions, it remains unclear whether the replacement of ω-6 PUFAs with ω-9 MUFAs results in improved efficacy and safety. To address this shortcoming, the objectives of this study were to assess the delivery, efficacy, and safety of an olive oil-based lipid PN regimen compared with a compounded soybean oil-based lipid PN regimen in Chinese adults for whom oral or enteral nutrition was not possible, insufficient, or contraindicated.

Methods

Study design

The study was an open-label, prospective, randomized (1:1), comparative, multi-center, active-controlled, parallel-group investigational trial (NTC 01579097) conducted in 18 centers across China. Ethics approval was obtained from the Institutional Ethics Committees and written informed consent was obtained before enrolment of any patients into the clinical trial. The study was conducted between December 29, 2011 and November 21, 2012 and was centrally administrated by Global Clinical Development & Operations (CD&O) based in Baxter Alliance Park, Belgium.

Study population

Patients admitted to a surgical service were eligible for enrolment into the trial if all of the following criteria (and none of the exclusion criteria) were met: aged ≥18 to ≤80 years old; an inpatient that was hospitalized ≤14 days before enrolment; required PN because oral or enteral nutrition was not possible, insufficient, or contraindicated; had the capability to complete at least five days of study treatment (ie, PN); had a useable peripheral vein for intravenous (IV) delivery of PN; and was able to complete written informed consent per national regulations. Exclusion criteria were: a life expectancy of <6 days from initiation of study treatment; a known hypersensitivity to the components of the study treatments; use of prohibited medications within 30 days before enrolment; a known serious clinically significant condition such as congestive heart failure or severe renal insufficiency (renal failure that was not compensated for by hemofiltration or dialysis; patients unable to tolerate fluid load from PN); impaired hepatic function (total bilirubin >2 times the upper limit of normal; or alanine transaminase >4 times the upper limit of normal; or aspartate transaminase >4 times the upper limit of normal); a known history of human immunodeficiency virus infection; known congenital abnormalities of amino acid metabolism; known severe dyslipidemia (triglyceride level >2 times the upper limit of normal or >400 mg/dL or >4.52 mmol/L) or hyperglycemia (blood glucose >360 mg/dL); clinically significant abnormalities of plasma electrolytes; currently pregnant or lactating; prior enrolment in this clinical trial; participation in a clinical trial of any
investigational drug or device concomitantly or within 30 days before enrolment in this clinical trial; or was considered unsuitable in the opinion of the Investigator. Due to clinical and resource constraints, consecutive patients were not enrolled at each center.

Treatment protocol

Patients were randomized to either an olive oil-based lipid PN regimen using OliClinomel N4 (OLIVE; Baxter Healthcare, Deerfield, IL, USA) or a compounded soybean oil-based lipid PN regimen using Intralipid (SOYBEAN; Sino-Swed Pharmaceutical Corporation, Ltd., Wuxi City, China).

OLIVE was supplied as a ready-to-use PN product presented as a three-chamber bag (1.5 l) comprising a larger outer chamber that contains a dextrose (D-glucose) solution (final mixed concentration 80 g/l) with calcium (final mixed concentration 2 mmol/l); a middle chamber that contains a solution of 15 amino acids (final mixed concentration 22 g/l), with electrolytes including sodium (final mixed concentration 21 mmol/L), potassium (final mixed concentration 16 mmol/l), magnesium (final mixed concentration 2.2 mmol/L), and phosphate (final mixed concentration 8.5 mmol/L); and a smaller outer chamber that contains a lipid emulsion comprising 80 % olive oil and 20 % soybean oil (final mixed concentration 20 g/l).

SOYBEAN was prepared as a compounded admixture by the institutional pharmacy (1.5 l), specifically the Pharmacy Intravenous Admixture Services if available, per the investigators’ prescription. Components were manufactured by: dextrose – 20 % Glucose 500 mL (Baxter (China) Investment Co., Ltd., Shanghai, China); amino acids – amino acid 15-AA 250 mL:20 g (8 %; Hunan Kelun Pharma Co., Ltd, Yueyang City, China); and lipid – Intralipid® 10 g/dL (Sino-Swed Pharmaceutical Corporation, Ltd., Wuxi City, China). The final concentrations of dextrose, protein, and lipid were the same as for OLIVE.

Electrolytes, vitamins, and trace elements could be added to the study treatment or compounded PN based upon patient requirements. The study treatment was infused through a peripheral IV catheter via a control pump. If continued infusion via a peripheral IV was not possible, the study treatment could be infused via a peripherally-inserted central catheter or central IV line.

Study treatment was administered for a minimum of five days and up to a maximum of 14 days (either 14 days after surgery or 14 days total for patients who did not undergo surgery). Study treatment could be initiated up to three days before surgery and was administered after surgery on Day 1 at Hour 0. Preoperative PN was not mandatory and if a patient did not receive study treatment before surgery, or if the patient was not scheduled for surgery, study treatment was initiated on Day 1 at Hour 0.

From Day 0 to Day 5, patients were not to receive any food or liquid oral or enteral nutrition. The goal of treatment was to deliver 25 kcal/kg/day, 0.9 g/kg/day amino acids, and 0.8 g/kg/day lipid. The patients were allowed water and ice chips based on the clinical judgment of the Investigator.

From Day 6 through the remainder of the study treatment period, liquid oral or enteral nutrition could be added to the study treatment. The intent was to supply the total calculated daily nutritional requirement with study treatment (intravenous nutrition) plus liquid oral or enteral nutrition. Liquid oral or enteral nutrition was increased daily, as tolerated by the patient, with a concurrent reduction in study treatment, while still supplying the calculated daily nutritional requirement.

Study treatment was ceased once the patient was able to achieve ≥80 % of the calculated daily nutritional requirements by administered liquid oral or enteral nutrition, or the completion of Day 14 study treatment, whichever occurred earlier.

Randomization

Assignment of study treatment was delegated by Baxter Healthcare Corporation to the study site pharmacist. Patient numbers were allocated using an Interactive Voice Recognition System/Interactive Web-based Recognition System according to the randomization code contained within the randomization list.

This was an open-label study. Treatment assignment was not known (ie, blinded) by the data management, biostatistical, and personnel at the central laboratory. In order to prepare the study treatment, the designated pharmacist was aware of the study treatment (unblinded). The study treatment was unblinded to the Investigator as it was standard practice that the physician and/or nurse carefully inspect the PN admixture to ensure that the integrity of the admixture was maintained throughout the length of the infusion.

Outcome measures

The primary efficacy variable was the serum prealbumin level at Day 5. Secondary efficacy outcome(s) included preparation time of study treatment, time to achieve tolerability of oral nutrition, length of hospitalization, lipids and lipid upper derivatives (arachidonic acid, eicosapentaenoic acid [EPA], linoleic acid, oleic acid), markers of infection and inflammation (cortisol, CRP, procalcitonin, serum ICAM-1, IL-6), markers of oxidative stress (malondialdehyde, F2-isoprostane), surrogate markers of nutrition (albumin, IGF-1), urine markers of metabolism (6-h urinary urea, 3-methylhistidine), and injection site rating by the Investigator. Safety outcomes included total adverse events (AEs), liver function, and infections. Infections were based upon the clinical
judgment of the investigators and utilized cultures when possible. Antibiotics were administered for all infections. Lung infections were defined as: the new onset of fever and/or leukocytosis with or without alterations in mela-
tation, purulent sputum or organisms on smear or cul-
ture, and a new progressive or persistent infiltrate on chest X-ray consistent with pneumonia (with no other obvious cause). Scrotal infection was diagnosed by the presence of fever and/or leukocytosis, new evidence of infection in the scrotum (pain, tenderness, swelling, heat, redness), and no other recognized cause for the abnormality. Non-specific infection was diagnosed in a patient with new fever, leukocytosis, tachycardia, tachypnea and no other obvious cause for the abnormalities, and a response to antibiotic treatment. These outcomes were approved by the China State Food and Drug Administration as being sufficient to register the OLIVE product in China.

Statistical analysis
A sample size of approximately 200 patients (98 per study treatment) would provide 90% power to claim non-inferiority between groups for prealbumin at Day 5. The primary comparison was that OLIVE was not inferior to the SOYBEAN in maintaining or increasing serum prealbumin levels. In the sample size calculation, it was assumed that the true ratio was 1, the coefficient of vari-
ance (CV) was 0.5, and the non-inferiority margin was –20%. These assumptions resulted in a sample size of 98 patients per study treatment. It was decided to enroll at least 200 patients per treatment group with an evalu-
able primary endpoint to generate additional clinical data for this study. The sample size was calculated by PASS version 2011. Approximately 500 subjects were randomized to achieve 400 subjects who had efficacy as-
sements on Day 5, assuming up to 20% of randomized subjects would drop out of the study before the Day 5 assessments.

The primary comparison was that OLIVE is not inferior to SOYBEAN in maintaining or increasing serum prealburi-
min levels. Noninferiority was claimed if the anti-log of the lower bound of the 95% confidence interval (CI) of the treatment difference was at least 0.80.

Analyses were performed on the intention-to-treat population (ITT), defined as all patients randomized. The primary efficacy analyses were based on the modified intention-to-treat (mITT) population, defined as all ITT patients who received study treatment and provided some efficacy data. The per protocol (PP) population was defined as the subset of ITT patients who had no major protocol violations and had Day 5 efficacy data. All safety analyses were conducted on the safety population, defined as all patients who received any amount of study treatment.

Unless otherwise stated, all statistical analyses were performed using a two-sided hypothesis test at the 5% level of significance. No adjustment for Type I error rate was required for the analysis of the primary endpoint because the study had only one primary endpoint with one comparison. Due to the large sample size there was no need to test the model assumptions (ie, normality test).

The primary efficacy variable was the serum prealbumin level at Day 5. The log transformed primary efficacy variable was analyzed via an analysis of covariance (ANCOVA) model with treatment and study site as the main effects and baseline serum prealbumin as the co-
ariate. The least square (LS) mean ± standard deviation (SD) estimates of the treatment effects for OLIVE and the control, as well as the two-sided 95% CI of the geo-
metric mean ratio of test/control was derived.

Preparation time of study treatment (Days 1 to 5) and length of hospitalization were summarized by treatment group. Differences between treatment groups were ana-
yzed using Kruskal-Wallis test. Time to achieve toler-
ability of oral nutrition was summarized using the Kaplan-Meier method and compared using a log-rank test. Other secondary efficacy variables were analyzed the same way as the primary variable with change from baseline and ANCOVA model on log-scale with baseline as covariate and treatment and study site as main effects. Injection site rating by the Investigator was analyzed using the Cochran-Mantel-Haenszel test with modified ridit scores.

For the safety analyses, statistical comparisons were performed between the two treatment groups. Continu-
ous data were compared using an ANOVA and catego-
dical data were compared using a Chi-square test/Fisher's exact test. AE relationship and severity were compared using Cochran-Mantel-Haenszel test with modified ridit scores. AEs were coded according to the Medical Dic-

tionary for Regulatory Activities (MedDRA).

All statistical analyses were completed using SAS ver-

sion 9.2 (SAS Institute Inc, Cary, North Carolina USA).

Results
Patient disposition
A total of 480 patients consented (Fig. 1) and 458 patients were enrolled and randomized into the study. All randomized patients were included in the ITT population, 226 (100.0%) patients in the OLIVE group and 232 (100.0%) patients in the SOYBEAN group. The safety population comprised 222 (98.2%) patients in the OLIVE group and 231 (99.6%) patients in the SOY-
BEAN group. The mITT population comprised 219 (96.9%) patients in the OLIVE group and 224 (96.6%) patients in the SOYBEAN group. The PP population comprised 183 (81.4%) patients in the OLIVE group and 190 (81.9%) in the SOYBEAN group. Similar
percentages of patients discontinued from the study in the OLIVE group (8.8 %) and the SOYBEAN group (10.3 %). The main reasons for discontinuation in both groups were patient withdrew consent and AEs (Fig. 1).

Demographic and baseline clinical characteristics
The demographic and baseline clinical characteristics of patients in the OLIVE and the SOYBEAN groups (ITT population) were not different (Table 1). Most patients were male (61 %, 279/458), identified as Chinese Han (95 %, 436/458), and had a mean age of 56 years. Most patients underwent surgery and experienced high complexity surgery (62 %, 283/458) with a mean duration of 3 h.

Nutritional intakes
Treatment exposure and doses administered were similar between the treatment groups. The mean ± SD durations of study treatment exposure were 8.4 ± 3.7 days in the OLIVE group and 8.2 ± 3.7 days in the SOYBEAN group. The mean ± SD doses administered were 16761.0 ± 7086.8 mL in the OLIVE group and 16877.5 ± 7453.0 mL in the SOYBEAN group. There were no statistically significant differences in the mean ± SD flow rate, total volume prescribed, total volume administered, volume ratio (prescribed/administered volume), total duration prescribed, total duration administered, or duration ratio (prescribed/administered duration) between the treatment groups (data not shown). There was no statistically significant difference between the time to

Table 1

| Variable                        | OLIVE (n = 226) | SOYBEAN (n = 232) | P Value |
|--------------------------------|----------------|-----------------|--------|
| Sex, n (%)                     |                |                 | 0.482  |
| Male                           | 134 (59.3)     | 145 (62.5)      |        |
| Female                         | 92 (40.7)      | 87 (37.5)       |        |
| Race, n (%)                    |                |                 | 0.673  |
| Chinese Han                    | 216 (95.6)     | 220 (94.8)      |        |
| Chinese other minority         | 8 (3.5)        | 11 (4.7)        |        |
| Other                          | 2 (0.9)        | 1 (0.4)         |        |
| Age, years, mean ± SD          | 55.8 ± 13.1    | 56.3 ± 11.7     | 0.656  |
| BMI, kg/m², mean ± SD          | 21.7 ± 3.9a    | 21.8 ± 3.9b     | 0.667  |
| Underwent surgery, n (%)       | 195 (86.3)     | 202 (87.1)      | 0.805  |
| Complexity of surgery, n (%)   |                |                 | 0.859  |
| Medium complexity              | 49 (21.7)      | 48 (20.7)       |        |
| High complexity                | 140 (61.9)     | 143 (61.6)      |        |
| Missing                         | 37 (16.4)      | 41 (17.7)       |        |
| Duration of surgery, hours, mean ± SD | 2.9 ± 1.3 | 3.0 ± 1.4 | 0.645  |

Abbreviations: BMI body mass index, SD standard deviation

a

b

Complexity of surgery was determined by the investigator based on patient and surgical characteristics

Figure 1

Patient disposition flowchart.

| Assess for eligibility (n = 480) |
|--------------------------------|
| Screening failures (n = 22)    |
| Randomized (N = 458)           |
| Allocated to OLIVE (N = 226)   |
| Completed 5 days of study treatment (n = 211, 93.4%) |
| Completed study treatment (n = 209, 91.2%) |
| Discontinued (n = 20) Reasons |
| Withdrew consent (n = 10)     |
| Adverse events (n = 7)        |
| Investigator-determined medical decision (n = 1) |
| Other reason (n = 2)          |
| Allocated to SOYBEAN (N = 232) |
| Completed 5 days of study treatment (n = 219, 94.4%) |
| Completed study treatment (n = 208, 89.7%) |
| Discontinued (n = 24) Reasons |
| Withdrew consent (n = 8)      |
| Adverse events (n = 11)       |
| Protocol violation (n = 1)    |
| Investigator-determined medical decision (n = 3) |
| Other reason (n = 3)          |
achieve adequate enteral intake (following 5 days of PN) for the OLIVE group and the SOYBEAN group (median time: OLIVE 2.0 days versus SOYBEAN 2.0 days; log rank \(P = 0.786\)).

**Anabolic/catabolic endpoints**

OLIVE was noninferior to SOYBEAN in maintaining or increasing serum prealbumin levels at Day 5 in the mITT population (LSGM ratio and [95 % CI] 1.12 [1.06, 1.19]; \(P = 0.0002\)) and the PP population (LSGM and [95 % CI] 1.12 [1.05, 1.19], \(P = 0.0006\)) (Fig. 2). This observation was consistent in the subgroup analyses of age, gender, no surgery, surgery of medium complexity, and surgery of high complexity (Fig. 2).

Serum prealbumin levels and serum albumin levels were significantly higher in the OLIVE group compared with the SOYBEAN group at Day 5 (Table 2). Prealbumin and albumin increased in the OLIVE group and decreased in the SOYBEAN group. No significant difference in serum IGF-I levels were observed between the treatment groups at Day 5; however, at end of therapy (EOT)/Day 14, serum IGF-I levels were significantly higher in the OLIVE group compared with the SOYBEAN group. No significant between-group differences were observed in the 6-h urinary urea nitrogen and 6-h urinary excretion of 3-methylhistidine (Table 2).

**Lipid endpoints**

Significant increases in serum oleic acid levels were observed for both treatment groups; however, the increases in the OLIVE group were greater than those observed in the SOYBEAN group (Table 3). No statistically significant differences in serum levels of linoleic acid, arachidonic acid, and EPA were observed between treatment groups at any timepoint (Table 3).

**Inflammation, oxidation, and infections**

There was a very small but significant difference at Day 5 in the serum levels of IL-6 observed between the OLIVE and the SOYBEAN groups (Table 4). In both groups, IL-6 levels decreased. No significant differences in the serum levels of cortisol, procalcitonin, CRP, or ICAM-1 were observed between treatment groups. No significant differences in the serum levels of malondialdehyde or F2-isoprostane were observed at Day 5 or EOT/Day 14 (Table 4).

Significantly more patients in the SOYBEAN group (10.4 % [24/231]) than the OLIVE group (3.6 % [8/222]) experienced an infection or infestation (Table 5). Overall, the frequency of infections in the study was low (7.1 % [32/453]). The most common infections were lung infections, which were higher in the SOYBEAN group. The second most common infection was incision/wound infections. Bloodstream infections were not reported to occur in the study.

**Preparation time**

The preparation time for study treatment was significantly less for OLIVE compared with the SOYBEAN on all days assessed (\(P <0.001\) for all values [Fig. 3]).

**Hospital time and mortality**

There were no significant differences between the OLIVE group and the SOYBEAN group for the length of hospitalization from admission to discharge or for the length of hospitalization from randomization to discharge (Table 6). Five patients died during the study; one patient in the OLIVE group (cardiopulmonary failure) and four patients in the SOYBEAN group (severe pharyngeal hemorrhage, severe abdominal infection, severe hypovolemic shock and severe acute renal failure).

**Safety endpoints**

*Safety and tolerability*

Overall, the safety and tolerability profile of OLIVE was similar to SOYBEAN. The most common treatment-emergent AEs (TEAEs) occurring in greater than 5 % of
patients in both groups were pyrexia and infusion site swelling (Table 7). Discontinuations from the study were low, with seven patients in the OLIVE group and nine patients in the SOYBEAN group discontinuing from the study due to AEs.

There were no differences between groups in the severity of TEAEs ($P = 0.073$) or in the relationship of TEAEs to study treatment ($P = 0.393$) as considered by the Investigators. Most TEAEs were considered to be mild in severity in both the OLIVE group (77.6% [125/222] patients) and the SOYBEAN group (69.8% [118/231] patients). Severe TEAEs were reported in 2/222 (1.2%) patients in the OLIVE group and 10/231 (5.9%) patients in the SOYBEAN group. The severe TEAEs reported by the two patients in the OLIVE group were cardiopulmonary failure and acute myocardial infarction. The severe TEAEs reported by the patients in the SOYBEAN group were epistaxis,

### Table 2 Effects of OLIVE and SOYBEAN on Markers of Nutrition in Patients Receiving Parenteral Nutrition

| Nutrition Marker | OLIVE | SOYBEAN | OLIVE vs SOYBEAN |
|------------------|-------|---------|-----------------|
|                  | Visit | N       | Mean ± SD       | N       | Mean ± SD       | LSGM Ratio (95% CI) | P-value |
| Albumin (g/L)    | Baseline | 214 | 33.11 ± 5.75 | 220 | 33.23 ± 5.84 | 1.04 (1.01, 1.07) | 0.0139 |
|                  | Day 5 | 211 | 34.02 ± 5.32 | 216 | 32.93 ± 5.15 | 1.04 (1.01, 1.07) | 0.0139 |
|                  | EOT/Day 14 | 82 | 35.37 ± 5.86 | 78 | 35.55 ± 5.3 | 1 (0.96, 1.05) | 0.9393 |
| Prealbumin (mg/dL) | Baseline | 213 | 15.08 ± 4.64 | 219 | 15.15 ± 5.01 | . | . |
|                  | Day 5 | 217 | 15.66 ± 5.12 | 218 | 13.95 ± 5.05 | 1.12 (1.06, 1.19) | 0.0002 |
|                  | EOT/Day 14 | 210 | 17.24 ± 6.82 | 219 | 15.15 ± 6.37 | 1.16 (1.08, 1.24) | 0.0001 |
| Prealbumin (PP) (mg/dL) | Baseline | 182 | 14.82 ± 4.58 | 188 | 14.97 ± 5.02 | . | . |
|                  | Day 5 | 184 | 15.7 ± 5.01 | 190 | 14.19 ± 5.06 | 1.12 (1.05, 1.19) | 0.0006 |
|                  | EOT/Day 14 | 184 | 17.38 ± 6.96 | 193 | 15.37 ± 6.43 | 1.16 (1.07, 1.25) | 0.0002 |
| IGF-I (ug/L)     | Baseline | 214 | 107.31 ± 49.61 | 220 | 110.9 ± 55.34 | . | . |
|                  | Day 5 | 211 | 125.81 ± 64.35 | 218 | 121.15 ± 61.11 | 1.04 (0.96, 1.13) | 0.3437 |
|                  | EOT/Day 14 | 82 | 142.9 ± 70.16 | 78 | 125.27 ± 65.22 | 1.16 (1, 1.35) | 0.045 |
| 6-h urea nitrogen, urine (mmol/L) | Baseline | 211 | 124.02 ± 92.1 | 218 | 129.39 ± 78.47 | . | . |
|                  | Day 5 | 211 | 141.95 ± 100.85 | 216 | 151.82 ± 98.15 | 0.91 (0.8, 1.03) | 0.1271 |
|                  | EOT/Day 14 | 81 | 150.4 ± 100.19 | 76 | 144 ± 101.81 | 1 (0.82, 1.23) | 0.9797 |
| 6-h 3-Methylthistidine, urine (ug/mL) | Baseline | 211 | 1.32 ± 2.61 | 217 | 1.37 ± 1.56 | . | . |
|                  | Day 5 | 212 | 1.44 ± 4.29 | 216 | 1.11 ± 0.98 | 1.02 (0.9, 1.14) | 0.7791 |
|                  | EOT/Day 14 | 81 | 1.98 ± 2.18 | 77 | 1.74 ± 4.4 | 1.1 (0.87, 1.38) | 0.4224 |

### Abbreviations: CI confidence interval, EOT end of therapy, LSGM least square geometric mean, PP per protocol, SD standard deviation

### Table 3 Effects of OLIVE and SOYBEAN on Serum Free Fatty Acid Levels in Patients Receiving Parenteral Nutrition

| Free Fatty Acid | OLIVE | SOYBEAN | OLIVE vs SOYBEAN |
|-----------------|-------|---------|-----------------|
|                  | Visit | N       | Mean ± SD       | N       | Mean ± SD       | LSGM Ratio (95% CI) | P-value |
| Arachidonic Acid (ng/mL) | Baseline | 214 | 2582.36 ± 1628.43 | 219 | 2435.61 ± 1691.17 | . | . |
|                  | Day 5 | 211 | 1647.86 ± 1169.39 | 217 | 1657.64 ± 1109.07 | 0.96 (0.83, 1.1) | 0.5511 |
|                  | EOT/Day 14 | 82 | 1907.33 ± 1503.86 | 78 | 2061.49 ± 1368.59 | 0.82 (0.64, 1.06) | 0.127 |
| Eicosapentaenoic Acid (ng/mL) | Baseline | 214 | 6238.86 ± 10452.35 | 219 | 5162 ± 3904.17 | . | . |
|                  | Day 5 | 211 | 5492.24 ± 4259.41 | 217 | 5490.93 ± 3916.9 | 1.05 (0.91, 1.21) | 0.5148 |
|                  | EOT/Day 14 | 82 | 5604.48 ± 5433.61 | 78 | 4451.74 ± 3218.58 | 1.04 (0.75, 1.43) | 0.8314 |
| Linoleic Acid (ng/mL) | Baseline | 214 | 114371.89 ± 81968.03 | 219 | 106834.77 ± 74014.98 | . | . |
|                  | Day 5 | 211 | 122618.72 ± 74778.06 | 217 | 138023.51 ± 84529.99 | 0.89 (0.77, 1.04) | 0.1543 |
|                  | EOT/Day 14 | 82 | 120846.77 ± 101009.54 | 78 | 122106.26 ± 73206.47 | 0.76 (0.53, 1.09) | 0.1369 |
| Oleic Acid (ng/mL) | Baseline | 214 | 70758.12 ± 85210.57 | 219 | 63624.5 ± 44727.06 | . | . |
|                  | Day 5 | 211 | 85697.52 ± 52610.19 | 217 | 71773.72 ± 45452.38 | 1.22 (1.09, 1.37) | 0.0006 |
|                  | EOT/Day 14 | 82 | 81704.84 ± 58732.76 | 78 | 63965.58 ± 45050 | 1.11 (0.81, 1.51) | 0.517 |

### Abbreviations: CI confidence interval, EOT end of therapy, LSGM least square geometric mean, SD standard deviation
Pharyngeal hemorrhage, urinary tract infection, abdominal infection, hypovolemic shock, lung infection, pyrexia, hypokalemia, hypernatremia, ureteric fistula, renal failure acute, vomiting, and intestinal fistula.

Eight patients in the OLIVE group and 14 patients in the SOYBEAN group experienced serious AEs (SAEs). Overall, each SAE was reported by ≤1.1% of patients. All reported SAEs were considered by the

### Table 4: Effects of OLIVE and SOYBEAN on Markers of Inflammation and Infections in Patients Receiving Parenteral Nutrition

| Marker                   | Visit             | OLIVE N | Mean ± SD     | SOYBEAN N | Mean ± SD     | LSGM Ratio (95% CI) | P-value |
|--------------------------|-------------------|---------|---------------|-----------|---------------|---------------------|---------|
| Cortisol (nmol/L)        | Baseline          | 214     | 492.98 ± 284.67 | 219       | 499.61 ± 256.24 | 1.02 (0.95, 1.1)   | 0.5677  |
|                          | Day 5             | 212     | 371.97 ± 145.68 | 218       | 362.98 ± 130.29 | 0.9 (0.87, 1.04)   | 0.1617  |
|                          | EOT/Day 14        | 82      | 382.37 ± 193.88 | 78        | 395.31 ± 155.08 | 0.9 (0.87, 1.04)   | 0.1617  |
| C-Reactive protein (mg/L)| Baseline          | 214     | 54.56 ± 54.46   | 220       | 56 ± 51.13     |                     |         |
|                          | Day 5             | 211     | 42.33 ± 42.9    | 216       | 47.17 ± 42.92  | 0.95 (0.81, 1.12)  | 0.5503  |
|                          | EOT/Day 14        | 82      | 20.95 ± 34.44   | 78        | 21.92 ± 31.23  | 0.9 (0.62, 1.31)   | 0.5785  |
| Procalcitonin (ng/mL)    | Baseline          | 214     | 0.91 ± 0.15     | 219       | 1.19 ± 2.67    |                     |         |
|                          | Day 5             | 212     | 0.36 ± 0.97     | 218       | 0.44 ± 1.29    | 0.98 (0.86, 1.11)  | 0.717   |
|                          | EOT/Day 14        | 82      | 0.15 ± 0.2      | 78        | 0.28 ± 1.1     | 0.88 (0.71, 1.11)  | 0.283   |
| sICAM-1 (ug/L)           | Baseline          | 214     | 264.37 ± 127    | 220       | 260.97 ± 128.62|                     |         |
|                          | Day 5             | 209     | 321.56 ± 158.86 | 217       | 304.41 ± 154.53| 1.02 (0.94, 1.1)   | 0.6462  |
|                          | EOT/Day 14        | 81      | 337.84 ± 152.58 | 78        | 352.73 ± 197.27| 0.96 (0.85, 1.08)  | 0.4683  |
| Interleukin-6 (ng/L)     | Baseline          | 214     | 143.03 ± 271.46 | 220       | 191.72 ± 705.37|                     |         |
|                          | Day 5             | 211     | 19.63 ± 57.58   | 218       | 20.11 ± 44.19  | 0.82 (0.69, 0.96)  | 0.0173  |
|                          | EOT/Day 14        | ND      | ND              | ND        | ND             | ND                  |         |
| Malondialdehyde (nmol/L)| Baseline          | 214     | 12.46 ± 25.2    | 219       | 11.4 ± 21.93   |                     |         |
|                          | Day 5             | 211     | 13.57 ± 27.65   | 217       | 12.49 ± 23.13  | 0.97 (0.87, 1.08)  | 0.5865  |
|                          | EOT or Day 14     | 82      | 12.65 ± 27.81   | 78        | 10.77 ± 21.68  | 0.86 (0.71, 1.04)  | 0.115   |
| F2-Isoprostane (ng/mL)   | Baseline          | 214     | 0.13 ± 0.17     | 219       | 0.11 ± 0.14    |                     |         |
|                          | Day 5             | 211     | 0.19 ± 0.33     | 217       | 0.14 ± 0.2     | 1.13 (0.85, 1.5)   | 0.4006  |
|                          | EOT/Day 14        | 82      | 0.16 ± 0.21     | 78        | 0.18 ± 0.29    | 0.9 (0.58, 1.4)    | 0.6502  |

**Abbreviations:** CI confidence interval, EOT end of therapy, LSGM least square geometric mean, ND not detected, SD standard deviation, sICAM serum intercellular adhesion molecule-1

Table 5: Treatment Emergent Infections

| Infection, n (%) | OLIVE (n = 222) | SOYBEAN (n = 231) |
|------------------|-----------------|-------------------|
| Total infections | 8 (3.6%)        | 26* (10.4%)       |
| Total patients infected | 8 (3.6%) | 24* (10.4%)       |
| Lung infections  | 2               | 13*               |
| Incision/Wound site infections | 5 | 3 |
| Urinary tract infections | 1 | 2 |
| Abdominal/gastrointestinal infections | 0 | 2 |
| Scrotal infections | 0 | 1 |
| Nonspecific infections (systemic infection, site not identified) | 0 | 5 |

*P < 0.01

**Figure 3** Preparing time of study treatment (Day 1 through Day 5). *P < 0.05 by Kruskal-Wallis. Error bars indicate standard deviations.
Investigator to be not associated or unlikely to be related to the study treatment. Most SAEs were considered by the Investigator to be moderate or severe and recovered/resolved with no sequelae by the end of the study.

**Systemic safety**

Alanine aminotransferase and aspartate aminotransferase were higher in the SOYBEAN group at baseline (Table 8). There were no statistically significant differences between groups at Day 5 or EOT/Day 14 and mean values were within normal limits or only slightly above the normal range. However, when analyzed for change from baseline, alanine aminotransferase was significantly different between groups at Day 5 and EOT/Day 14, whereas aspartate aminotransferase was not significantly different between groups. Alkaline phosphatase was similar between groups at baseline. Levels were significantly different between groups at Day 5 but not at EOT/Day 14. Most values were within normal ranges. Gamma-glutamyltransferase was within normal limits for most patients and similar between groups at baseline. When analyzed by change from baseline, gamma-glutamyltransferase values were higher in the OLIVE group than in the SOYBEAN group at Day 5, but not at EOT/Day 14. Total bilirubin was similar between groups at all time points. Blood urea nitrogen was similar between groups at baseline. When analyzed by change from baseline, blood urea nitrogen values were higher in the OLIVE group at Day 5 but not at EOT/Day 14. Most values remained within normal limits throughout the study.

**Table 6** Effects of OLIVE and SOYBEAN on Hospital Time in Patients Receiving Parenteral Nutrition

| Length of Hospitalization                  | OLIVE | SOYBEAN | OLIVE vs SOYBEAN |
|--------------------------------------------|-------|---------|------------------|
|                                            | N     | Mean ± SD | Median | N     | Mean ± SD | Median | P-value   |
| From admission to discharge, days          | 219   | 16.92 ± 4.99 | 16     | 224   | 18.1 ± 8.65 | 16     | 0.7823    |
| From randomization to discharge, days      | 219   | 10.84 ± 4.27 | 10     | 224   | 12.04 ± 7.82 | 10     | 0.4854    |

*Abbreviations: SD standard deviation*

**Table 7** Study Drug-Related Adverse Events in the Safety Population

| System Organ Class Preferred Term         | OLIVE | SOYBEAN |
|-------------------------------------------|-------|---------|
|                                           | Frequency a | n (%) b | Frequency a | n (%) b |
| General disorders and administration site conditions | 164   | 85 (38.3) | 157   | 89 (38.5) |
| Swelling                                  | 60    | 19 (8.6)  | 50    | 17 (7.4)  |
| Pyrexia                                    | 38    | 33 (14.9) | 40    | 35 (15.2) |
| Infusion site swelling                     | 20    | 16 (7.2)  | 26    | 24 (10.4) |
| Gastrointestinal disorders                 | 65    | 43 (19.4) | 72    | 50 (21.6) |
| Nausea                                     | 22    | 17 (7.7)  | 19    | 17 (7.4)  |
| Vascular disorders                         | 47    | 33 (14.9) | 65    | 41 (17.7) |
| Phlebitis                                  | 24    | 12 (5.4)  | 31    | 12 (5.2)  |
| Peripheral vascular disorder               | 14    | 13 (5.9)  | 23    | 22 (9.5)  |
| Metabolism and nutrition disorders         | 35    | 28 (12.6) | 60    | 42 (18.2) |
| Hypokalemia                                | 3     | 3 (1.4)   | 18    | 18 (7.8)  |
| Investigations                             | 41    | 27 (12.2) | 38    | 26 (11.3) |
| Gamma-glutamyltransferase increased        | 11    | 11 (5.0)  | 7     | 7 (3.0)   |
| Injury, poisoning and procedural complications | 44    | 27 (12.2) | 30    | 25 (10.8) |
| Procedural pain                            | 21    | 12 (5.4)  | 9     | 7 (3.0)   |
| Incision site pain                         | 16    | 12 (5.4)  | 12    | 10 (4.3)  |
| Respiratory, thoracic and mediastinal disorders | 31    | 23 (10.4) | 26    | 20 (8.7)  |
| Productive cough                           | 14    | 14 (6.3)  | 11    | 11 (4.8)  |
| Cough                                      | 11    | 11 (5.0)  | 11    | 11 (4.8)  |
| Infections and infestations                | 8     | 8 (3.6)   | 26    | 24 (10.4) |
| Hepatobiliary disorder                     | 13    | 13 (5.9)  | 7     | 7 (3.0)   |

*aNumber of events
bNumber and percentage of patients with at least one event*
Creatinine remained normal in both groups throughout the study; there were no differences between groups.

For the change from baseline in serum electrolytes, statistically significant differences in chloride (Day 5 and EOT/Day 14), phosphorus (Day 5 and EOT/Day 14), and potassium (Day 5 and EOT/Day 14) were observed (Table 8). Bicarbonate, chloride, phosphorus, potassium, and sodium levels were within normal limits in both treatment groups at Day 5 and EOT/Day 14.

Cholesterol increased more in the OLIVE group compared to the SOYBEAN group, but values remained within normal limits in most patients (Table 8). Triglyceride levels increased in both groups, reflecting the triglyceride content of the lipid emulsions. Values were

### Table 8 Absolute Serum Chemistry Measures in the Modified Intention to Treat Population

| Serum Chemistry Measure                      | Visit          | OLIVE N | Mean ± SD | SOYBEAN N | Mean ± SD | LS Mean ± SE (95 % CI) | p-value |
|---------------------------------------------|----------------|---------|-----------|-----------|-----------|------------------------|---------|
| Alanine aminotransferase, U/L               | Baseline       | 212     | 41.4 ± 87.15 | 216       | 73.3 ± 197.14 |                       |         |
|                                             | Day 5          | 79      | 31.0 ± 27.86 | 85        | 29.2 ± 55.41 | 21.3 ± 6.89 (7.7, 34.9) | 0.002   |
|                                             | EOT/Day 14     | 201     | 48.8 ± 61.23 | 196       | 38.5 ± 38.70 | 42.5 ± 15.24 (12.5, 72.5) | 0.006   |
| Alkaline phosphatase, U/L                   | Baseline       | 210     | 72.5 ± 46.87 | 212       | 71.7 ± 35.65 |                       |         |
|                                             | Day 5          | 79      | 87.7 ± 58.27 | 85        | 74.7 ± 40.41 | 18.8 ± 6.56 (7.7, 30.0) | 0.001   |
|                                             | EOT/Day 14     | 201     | 123 ± 96.24  | 196       | 106.9 ± 70.89 | 11.6 ± 7.72 (−3.6, 26.8) | 0.133   |
| Aspartate aminotransferase, U/L             | Baseline       | 210     | 52.8 ± 117.38| 212       | 72.3 ± 191.38|                       |         |
|                                             | Day 5          | 79      | 31.9 ± 19.27 | 85        | 22.6 ± 15.82 | 22.4 ± 8.87 (4.9, 40.0) | 0.12    |
|                                             | EOT/Day 14     | 201     | 35.8 ± 39.42 | 196       | 30.6 ± 35.13 | 25.5 ± 17.25 (−8.5, 59.4) | 0.141   |
| γ-Glutamyltransferase, U/L                  | Baseline       | 210     | 39.2 ± 74.63 | 212       | 42.7 ± 70.32 |                       |         |
|                                             | Day 5          | 79      | 100.5 ± 136.62| 85       | 68.9 ± 71.69 | 34.9 ± 11.96 (11.3, 58.5) | 0.004   |
|                                             | EOT/Day 14     | 201     | 139.2 ± 165.89| 196     | 118.1 ± 140.65| 12.4 ± 13.45 (−14.1, 38.8) | 0.358   |
| Total bilirubin, μmol/L                     | Baseline       | 212     | 18.00 ± 15.98| 216       | 16.12 ± 10.69 |                       |         |
|                                             | Day 5          | 79      | 13.21 ± 9.76 | 85        | 11.86 ± 9.56 | −0.39 ± 1.50 (−3.35, 2.56) | 0.793   |
|                                             | EOT/Day 14     | 201     | 12.86 ± 9.34 | 196       | 13.87 ± 18.94 | −2.97 ± 1.42 (−5.76, −0.19) | 0.36    |
| Blood urea nitrogen, mmol/L                 | Baseline       | 212     | 67.8 ± 23.6  | 218       | 67.4 ± 21.1 |                       |         |
|                                             | Day 7          | 110     | 62.0 ± 15.8  | 112       | 60.2 ± 17.4 | −2.3 ± 2.7 (−7.5, 3.0) | 0.40    |
|                                             | EOT/Day 14     | 200     | 62.6 ± 16.5  | 195       | 62.2 ± 16.7 | −0.7 ± 1.7 (−4.1, 2.7) | 0.69    |
| Creatinine, μmol/L                          | Baseline       | 212     | 104.4 ± 4.33 | 216       | 103.7 ± 4.39 |                       |         |
|                                             | Day 5          | 85      | 101.4 ± 3.55 | 93        | 102.4 ± 4.53 | −1.6 ± 0.73 (−3.1, −0.2) | 0.027   |
|                                             | EOT/Day 14     | 200     | 101.0 ± 3.55 | 194       | 101.8 ± 5.03 | −1.3 ± 0.59 (−2.5, −0.1) | 0.030   |
| Phosphorus, mmol/L                          | Baseline       | 155     | 1.07 ± 0.26  | 162       | 1.15 ± 0.79 |                       |         |
|                                             | Day 5          | 83      | 1.21 ± 0.47  | 89        | 0.98 ± 0.45 | 0.25 ± 0.09 (0.09, 0.42) | 0.003   |
|                                             | EOT/Day 14     | 183     | 1.26 ± 0.21  | 176       | 1.20 ± 0.32 | 0.17 ± 0.08 (0.00, 0.34) | 0.044   |
| Potassium, mmol/L                           | Baseline       | 212     | 4.58 ± 9.07  | 216       | 3.98 ± 0.47 |                       |         |
|                                             | Day 5          | 85      | 4.35 ± 0.57  | 93        | 3.95 ± 0.53 | 0.43 ± 0.10 (0.23, 0.63) | <0.001  |
|                                             | EOT/Day 14     | 201     | 4.97 ± 9.16  | 194       | 4.06 ± 0.53 | 0.28 ± 0.06 (0.15, 0.40) | <0.001  |
| Total cholesterol, mmol/L                   | Baseline       | 206     | 3.52 ± 0.95  | 210       | 3.60 ± 0.89 |                       |         |
|                                             | Day 5          | 77      | 3.48 ± 0.96  | 84        | 7.60 ± 38.15 | −4.35 (−13.47, 4.77) | 0.348   |
|                                             | EOT/Day 14     | 196     | 3.76 ± 0.90  | 188       | 3.6 ± 0.94 | 0.20 (0.02, 0.39) | 0.029   |
| Triglycerides, mmol/L                       | Baseline       | 206     | 0.89 ± 0.53  | 211       | 0.91 ± 0.58 |                       |         |
|                                             | Day 5          | 77      | 1.89 ± 0.95  | 85        | 1.51 ± 0.68 | 0.41 (0.19, 0.63) | <0.001  |
|                                             | EOT/Day 14     | 200     | 1.72 ± 0.88  | 193       | 1.50 ± 0.67 | 0.25 (0.09, 0.40) | 0.002   |

Abbreviations: CI confidence interval, EOT end of treatment, LS least squares, SD standard deviation, SE standard error.
slightly, but significantly higher in the OLIVE group compared to the SOYBEAN group. No patient withdrew from the study due to lipid abnormalities (ie, elevated cholesterol or triglycerides) and none of the PN infusions required adjustment for lipid levels.

No statistically significant differences (all $P > 0.05$) between the OLIVE group and SOYBEAN group were observed for serum glucose or insulin use (Table 9). In addition, there were no significant differences between groups for insulin levels in the blood or hematological measures (basophils, neutrophils, eosinophils, lymphocytes, monocytes, platelets, hemoglobin, and hematocrit). Absolute counts for basophils, eosinophils, lymphocytes, monocytes, and neutrophils remained within normal ranges in both treatment groups (data not shown).

**Discussion**

This is the largest prospective, randomized, open-label, controlled, multi-center study to date that compares two lipid emulsions used as part of complete PN; an olive oil-based lipid emulsion PN regimen and a soybean oil-based lipid emulsion PN regimen. Overall, OLIVE was not inferior to SOYBEAN for prealbumin levels, improved the anabolic/catabolic status of patients enrolled in the study, and was well tolerated compared with SOYBEAN. The improvement in anabolic status for the OLIVE group was indicated by higher levels of the protein endpoints of prealbumin, albumin, and IGF-1. The lack of difference in urinary excretion of urea and 3-methylhistidine between the groups suggests that catabolism was similar in each group. CRP, ICAM-1, procollagen III, and oxidation were similar in each group, but infections were significantly lower with OLIVE. Oleic acid levels increased with OLIVE; but linoleic acid, arachidonic acid, and EPA were similar between groups. OLIVE was associated with shorter preparation times compared with the compounded SOYBEAN admixture.

Prealbumin was chosen as the primary endpoint for the study following discussion with a number of experts. Serum prealbumin levels are determined by a variety of factors, including synthesis, degradation, and tissue distribution. Synthesis is dependent upon supply of amino acids to the liver and activation of prealbumin synthetic pathways. During metabolic stress, as occurs with illness and surgery, activation of inflammatory pathways (especially IL-6) increase prealbumin degradation, limit its synthesis, and may increase tissue distribution by leakage into tissues (increased vascular permeability) [17]. Lipid emulsions and other components of PN have been shown to modulate endothelial permeability, inflammation, anabolism, catabolism, and immune cell functions [18]. As a result, prealbumin was thought to be a composite indicator of amino acid supply, protein synthetic capacity, catabolism, and inflammation. All of these endpoints are important targets for nutrition support and were assessed in this study. Anabolism was assessed with prealbumin, albumin, and IGF-1 levels; catabolism was assessed with nitrogen excretion and 3-methylhistidine excretion. In addition, we also assessed other endpoints that included infections, hospital stay, morbidities (AEs), mortality, organ function (renal, hepatic, hematologic), and metabolic status (oxidation, fatty acids, cholesterol, triglycerides, glucose, insulin, electrolytes).

OLIVE was associated with significant increases in prealbumin, albumin, and IGF-1 compared with SOYBEAN. As no difference between groups for catabolic markers were noted, these results would suggest that the effects of OLIVE are likely to be mediated by anabolism. IGF-1 is particularly sensitive to protein intake and responds rapidly to protein energy status [19]. This is the first study to compare the effects of an olive oil-based PN regimen with a soybean oil-based PN regimen on serum IGF-1 levels. While numerous studies have reported the positive nutritional effects of OLIVE on one or perhaps two nutritional markers [8, 20–22], this is the first study to examine both anabolic and catabolic marker profiles and one of the first studies to demonstrate that OLIVE is effective in increasing anabolism in critically ill patients. The exact mechanism for the differences in anabolism are unclear, but may relate to the high ω-6 PUFA levels in the SOYBEAN versus OLIVE emulsion that may exacerbate the inflammatory response to surgery and illness.

The physiologic response to injury is an acute phase reaction (APR) mediated by a sudden increase in cortisol and the production of proteins such as CRP and cytokines (IL-1, IL-6, tumor necrosis factor-α [TNFα]). APR proteins have direct effects on catabolism and

**Table 9** Serum Glucose Concentrations (mmol/L) and Insulin Use

|                | n   | OLIVE Mean ± SD | n   | SOYBEAN Mean ± SD | P-value (change from baseline between groups) |
|----------------|-----|-----------------|-----|-------------------|-------------------------------------------|
| Baseline       | 212 | 7.1 ± 2.3       | 216 | 7.2 ± 2.3         |                                            |
| Day 3          | 207 | 8.6 ± 3.1       | 218 | 8.4 ± 3.5         | 0.74                                      |
| Day 7          | 110 | 6.7 ± 2.6       | 112 | 7.0 ± 2.7         | 0.13                                      |
| EOT or Day 14  | 201 | 6.3 ± 2.2       | 193 | 6.9 ± 3.0         | 0.09                                      |
| Patients requiring insulin | 41 (18.5 %) | – | 48 (20.8 %) | – |

*Values are not significantly different at any time point; Abbreviations: EOT end of treatment, SD standard deviation
inflammatory pathways and, therefore, play a role in nutritional status, particularly in critically ill patients where malnutrition and systemic inflammation coexist [19]. Both OLIVE and SOYBEAN were associated with decreases in cortisol, CRP, and IL-6 levels. The effects of OLIVE and SOYBEAN on APR proteins were consistent with a prior smaller study that showed both lipid formulations were associated with decreases in CRP and TNFα [21]. Prior studies have also shown that OLIVE significantly lowers IL-6 levels compared with a medium chain triglyceride/long chain triglyceride (MCT/LCT) lipid emulsion, but no between-group differences in IL-6 were noted in two studies that compared OLIVE with SOYBEAN [14, 21, 23]. A limited number of acute phase proteins (ie, CRP, IL-6, procalcitonin, ICAM-1, cortisol) were assessed in this study and no differences between levels were observed. Oxidative markers (ie, MDA, F2-isoprostane) were also measured and no differences were found. It is possible that more frequent sampling, measurement of tissue levels rather than blood levels, or measurement of other markers (ie, leukocyte functions) may have shown differences between lipid groups.

SOYBEAN lipid emulsion contains high levels (approximately 54 %) of the ω-6 PUFA, linoleic acid, while OLIVE contains much lower levels (approximately 18 %). It has been hypothesized that the high levels of linoleic acid in SOYBEAN exacerbate inflammation [15, 16, 18, 24, 25] in patients undergoing acute illness and tissue injury (such as major surgery). However, we were unable to detect such exacerbation in this study using conventional inflammatory markers such as cortisol, IL-6, ICAM-1, CRP, and procalcitonin. It is possible that other inflammatory markers (such as leukotrienes) may have been higher in the SOYBEAN group than in the OLIVE group.

Small studies directly comparing olive oil-based lipid emulsions with soybean oil-based lipid emulsions have provided conflicting results, with some studies showing significant reductions in inflammatory and oxidative stress markers [23], while other studies have reported no differences in inflammatory or oxidative stress markers between olive oil-based PN and soybean oil-based PN admixtures [14, 21]. Furukawa and colleagues [12] investigated the impact that the degree of stress associated with surgery had on IL-6 production in patients receiving lipid-free or soybean oil-based PN admixtures. The results of their study showed that soybean oil-based PN significantly increased IL-6 levels in patients experiencing severe stress, but not in patients experiencing moderate stress. Several reasons may account for the differences between prior studies and this study including sample size, differences in the patient populations between the studies, or differences in the level of stress the patients were experiencing.

Measurement of lipids and lipid upper derivatives revealed changes in the levels of fatty acid moieties that were consistent with the lipid source contained in the two PN regimens. Not surprisingly, linoleic acid levels increased in both treatment groups, albeit to a lesser extent in the OLIVE group. Despite the trend for increased linoleic acid in the SOYBEAN group, arachidonic acid levels decreased similarly in both groups. Thus, supply of larger amounts of linoleic acid with SOYBEAN had no effect upon circulating arachidonic acid levels. The decrease in arachidonic acid levels in both groups suggests that it was being consumed as substrate for the APR. It is important to note that tissue levels of these fatty acids, not measured in this study, may better reflect cellular effects of the fatty acids. Similarly, the significantly greater increase in oleic acid observed in the OLIVE group compared with the SOYBEAN group is consistent with the olive oil contained in OLIVE. Cholesterol and triglycerides are components of the lipid emulsions used in both groups. Cholesterol increased to a greater extent in the OLIVE group; however, differences in levels were small and unlikely to have clinical significance. Cholesterol levels remained within normal limits (ie, <5.2 mmol/L) in most patients. Triglyceride levels increased in both study groups, reflecting the infusion of triglycerides in the lipid emulsions. Levels increased slightly but significantly more in the OLIVE group. Most levels remained below the upper recommended triglyceride level for parenteral nutrition (ie, 3.5−4.5 mmol/L). The greater increase in triglycerides in the OLIVE group likely reflects the slightly slower clearance of olive oil-based triglycerides compared to soybean triglycerides.

One of the most clinically relevant findings of this study was the decreased incidence of infections in the OLIVE group compared to the SOYBEAN group. There were many similarities between the two groups including rate and complexity of surgery, duration of stay in hospital, duration of PN, and glucose levels. Therefore, these factors do not explain the difference in infection rate.

Studies comparing compounded PN with multichamber PN have shown that compounded PN is associated with a higher rate of bloodstream infections [26]. However, in this study we did not see a difference in bloodstream infections between groups, as most infections were of pulmonary origin followed by incision site infections and urinary tract infections. Small studies have also reported that the use of soybean oil-based lipid emulsions is associated with an increased risk of infections [15]. This effect is believed to be a result of the proinflammatory and immunosuppressive effects of the high linoleic acid content of soybean oil-based emulsions [15, 16, 27]. However, it should be noted that the overall
rate of infections in this study was low, as is typically seen in elective surgery populations. Historically, infection rates in patients receiving total PN have been much higher. Prior studies have suggested that lipid emulsions that are high in oleic acid may have less impact on the immune system compared with soybean oil-based lipid emulsions [15, 17, 28, 29]. In contrast, a recent study comparing SOYBEAN with OLIVE reported that there were no differences in immune cell functions in 100 intensive care unit (ICU) patients [21]. Thus, the causes or mechanisms responsible for the different incidences of infection between groups remains unclear.

Manzanares et al. [30] performed a systematic review of randomized clinical studies comparing lipid emulsions with low versus high linoleic acid (n-6 polyunsaturated fatty acid) levels in critically ill patients. However, patients with elective surgery were excluded from the analyses. Thus, the results of this systematic review may not be applicable to elective surgery patients (studied in the present trial). Overall, the lower linoleic acid formulations in the studies demonstrated trends toward lower mortality (relative risk [RR] 0.83, 95% CI 0.62, 1.11, \( P = 0.2 \)), duration of mechanical ventilation (−2.57 days, 95% CI −5.51, 0.37, \( P = 0.09 \)), and ICU length of stay (−2.31 days, 95% CI −5.28, 0.66, \( P = 0.13 \)). There was no difference between formulations for total infections (RR 1.13, 95% CI 0.87, 1.46, \( P = 0.35 \)). Four of the 12 studies in the review used an olive oil-based lipid emulsion and compared it to MCT/LCT (2 trials) or soybean emulsion (2 trials). In this subset of studies, there was no difference between groups for mortality or ICU length of stay. Total infections tended to be higher in the olive group (RR 1.23, 95% CI 0.92, 1.63, \( P = 0.16 \)) whereas ventilation time was significantly lower in the olive group (−6.47, 95% CI −11.4, −1.5, \( P = 0.01 \)).

The preparation time of PN solutions was significantly less for OLIVE than for the SOYBEAN PN admixture. One of the goals of this study was to assess current methods of PN delivery in Chinese ICUs. Historically, lipid emulsions have been administered separately from the PN solution because of the storage requirements for the emulsion. With the advent of multi-chamber PN systems it is now possible to provide a simultaneous and continuous infusion of all nutrients using a single pump and IV line [31]. Evidence suggests that the use of these systems reduces the risk of microbial contamination due to reduced handling, reduces the risk of bloodstream infections, decreases the risk of error, decreases nursing time, and decreases risk of physical instability of the PN mixture [31–33]. Health economic investigations also suggest that multi-chamber PN systems can reduce costs associated with the manpower required to prepare compounded PN admixtures [34, 35]. When compounding PN admixtures, special attention needs to be paid to aseptic technique, the order of mixing, the presence of residual air in the bag, the type of bag material, and the storage conditions in order to prevent failure or contamination of the admixture. These factors all affect the amount of preparation time needed to prepare these solutions [36, 37]. Further, preparation of compounded admixtures requires specially trained staff and/or specialized automated equipment, whereas use of pre-prepared multi-chamber bag systems only requires proper inspection of the solutions before initiation of the infusion [38].

No differences in the clinical outcomes of length of hospitalization, mortality, or time to achieve tolerability of oral nutrition were observed between the treatment groups. However, other clinically relevant outcomes such as quality of life, functional status, or rehospitalization rates were not assessed in this study. Several small studies have reported that olive oil-based parenteral nutrition is associated with reductions in the duration of mechanical ventilation [22, 39] and length of stay in the ICU [22]. In contrast, other larger studies have reported no difference in the length of hospital stay or ICU length of stay between olive oil-based and soybean oil-based admixtures [21, 26]. However, it is likely that the differences observed between the current study and prior studies relate to the small sample sizes or to the specific patient populations enrolled in the studies.

OLIVE was well tolerated and no significant differences in the frequency or severity of TEAEs were observed between the treatment groups. In addition, the frequency of TEAEs leading to discontinuation of study drug was low. The incidence of hepatobiliary AEs was low and not different between groups. The liver enzymes, alanine aminotransferase and aspartate aminotransferase, were different between groups at baseline. Levels were significantly higher in the olive group (RR 1.23, 95% CI 0.92, 1.63, \( P = 0.16 \)) whereas ventilation time was significantly lower in the olive group (−6.47, 95% CI −11.4, −1.5, \( P = 0.01 \)).

The increase in both enzymes suggests that both PN regimens were associated with mild cholestasis. Cholestasis has been associated with long-term use of PN; however, it is unclear whether the changes reflect the use of PN or reflect changes following
abdominal surgery. Importantly, total bilirubin was similar between groups and most patients had values within normal limits. The clinical relevance of these findings is unclear. Perhaps a longer duration of PN would have revealed additional information. Whether these early changes are important in the context of long-term PN cannot be determined from this study; however, short-term PN with OLIVE or SOYBEAN did not appear to negatively impact liver function.

Clinical chemistry measures remained within normal limits in both treatment groups for the duration of the study. Small statistically significant differences were noted between groups and once again, the clinical relevance remains unclear. Of note, potassium and phosphorus levels were better maintained within normal ranges in the OLIVE group compared to the SOYBEAN group. The better maintenance of phosphorus levels may have resulted from the use of organic phosphorus in OLIVE compared with inorganic phosphorus in SOYBEAN. Organic phosphorus has a longer circulation time than inorganic phosphorus since it is not directly filtered in the urine, allowing more time for entry of phosphorus into cells. Overall, the results of the study suggest that OLIVE has a safety profile that makes it suitable for use in ill patients requiring PN.

The internal and external validity of this study are strengthened by the prospective, randomized, controlled, and multi-center study design. Although the study was open label, which may have contributed to bias in the reporting of treatment effects, it was not feasible to conduct a blinded study because it is standard practice that the physician and/or nurse carefully inspect the PN formulations to ensure that the integrity of the admixture (technically an emulsion) is maintained throughout the length of the infusion. In addition, the study is one of the largest (N = 458) to compare the efficacy and safety of two PN regimens in well-matched study populations and there was consistency in the findings across a variety of endpoints. The maximum duration of PN administration was 14 days, which is typical for elective surgery patients who usually receive PN for 7 to 10 days following surgery, as enteral feeding is gradually increased. However, the relatively short duration of follow-up (a maximum of 14 days) may be considered a limitation. Despite this, it is possible that a longer duration of PN administration may have resulted in additional differences between the treatment groups.

In conclusion, OLIVE improved the anabolic/catabolic status of hospitalized adults compared to SOYBEAN and was well tolerated. OLIVE was non-inferior to SOYBEAN for prealbumin and significantly increased prealbumin, albumin, and IGF-1 serum levels to a greater extent than SOYBEAN. Inflammation and oxidation were similar in each group, but infections were significantly lower with OLIVE. The results of this study suggest that an olive oil-based PN regimen improves nutritional outcomes, lowers infections, is well tolerated, and confers greater ease-of-use compared with a compounded soybean oil-based PN regimen.

Abbreviations
AE: Adverse event; CI: Confidence interval; CRP: C-reactive protein; CV: Coefficient of variance; EOT: End of therapy; EPA: Eicosapentaenoic acid; ICAM-1: Intercellular adhesion molecule-1; ICU: Intensive care unit; IGF-1: Insulin-like growth factor-1; IL-6: Interleukin-6; ITT: Intention-to-treat population; IV: Intravenous; LS: Least square; LSM: Least square geometric mean; mITT: Modified intention-to-treat population; MUFA: ω-9 monounsaturated fatty-acids; PN: Parenteral nutrition; PP: Per protocol; PUFA: ω-6 polyunsaturated fatty acids; SAE: Serious adverse event; SD: Standard deviation; TEAE: Treatment-emergent adverse event; TNFa: Tumor necrosis factor-α.

Competing interests
ZYJ, JY, YX, DNT, and HLQ have no conflicts of interest to declare. GPZ is a Senior Medical Director for Baxter Healthcare, the sponsor of this study.

Authors’ contributions
All authors participated in the drafting, critical revision, and approval of the final version of the manuscript. ZYJ, GPZ, and HLQ were involved in the study design. ZYJ, HLQ, GPZ, and JY were involved in data analyses. ZYJ, JY, YX, and DNT were investigators in the study and HYD (OliClinomel China Study Group Statistician) conducted the statistical analysis.

Acknowledgments
This study was sponsored by Baxter Healthcare, manufacturer/licensee of OliClinomel N4. Baxter Healthcare was involved in the study design, data collection, data analysis, and preparation of the manuscript. Medical writing assistance was provided by Tania Dickson, PhD and Serina Strettom, PhD, CMPP of ProScribe, part of the Envision Pharma Group and was funded by Baxter Healthcare. ProScribe’s services complied with international guidelines for Good Publication Practice (GPP2).

Other contributors/acknowledgements
OliClinomel China Study Group, consisting of Zhengjun Qiu, Wei Li, Xiaojing Jiang, Bo Peng, Jiaozeng Xia, Daorong Xu, Feizhou Huang, Ningwei Zhang, Hongming Pan, Shunrong Huang, Yanbing Zhou, Jianjiang Lin, Jiafu Ji, Zhenli Zhou, Zhangming Li, Heng Gao, Xuefeng Zhang, Hongyan Du. a. Shanghai No. 1 People’s Hospital b. The First Affiliated Hospital Shantou University School of Medicine c. Shanghai Eastern Hepatobiliary Hospital d. Haikou People’s Hospital e. Wuxi No. 2 People’s Hospital f. Peking University Third Hospital g. The Third Xiangya Hospital of Central South University h. Beijing Shijitan Hospital i. Hangzhou Sr Runrun Shaw Hospital j. The People’s Hospital of Guangxi Zhuang Autonomous Region k. The Affiliated Hospital of Medical College Qingdao University l. First Affiliated Hospital College of Medicine, Zhejiang University m. Beijing Cancer Hospital n. Tianjin Nankai Hospital of TCM o. Central Hospital of Baotou p. Jiangsu Jiangyin People’s Hospital q. Shenyang Military General Hospital r. Senior Manager Biostatistics, Baxter Healthcare

Author details
1 Department of Surgery, Shanghai Sixth People’s Hospital, Affiliated to Shanghai Jiao Tong University, Shanghai 200233, China. 2 Baxter Healthcare, Deerfield, IL 60015, USA. 3 Department of Surgery, Shanghai Sixth People’s Hospital, Affiliated to Shanghai Jiao Tong University, Shanghai 200233, China. 4 General Surgery, Shanghai Tenth People’s Hospital (Tenth People’s Hospital of Tongji University), Shanghai 200072, China.
References

1. Berger MM. The 2013 Arvid Wretlind lecture: evolving concepts in parenteral nutrition. Clin Nutr. 2014;33(4):656–70.

2. Jie B, Jiang ZM, Nolan MT, Efros DT, Zhu SN, Yu K et al. Impact of nutritional support on clinical outcome in patients at nutritional risk: a multicenter, prospective cohort study in Baltimore and Beijing teaching hospitals. Nutrition. 2010;26(11–12):1088–93.

3. Jie B, Jiang ZM, Nolan MT, Zhu SN, Yu K, Kondrup J. Impact of preoperative nutritional support on clinical outcome in abdominal surgical patients at nutritional risk. Nutrition. 2012;28(10):1022–7.

4. Muller JL, Busby GP, Matthews DC, Smale BF, Rosato EF. Reduction of operative morbidity and mortality by combined preoperative and postoperative nutritional support. Ann Surg. 1980;192(5):604–13.

5. Wu MH, Lin MT, Chen WJ. Effect of perioperative parenteral nutritional support for gastric cancer patients undergoing gastrectomy. Hepatogastroenterology. 2008;55(02-03):799–802.

6. Mateu-de Antonio J, Grau S, Luque S, Marin-Casino M, Albert I, Ribes E. Comparative effects of olive oil-based and soybean oil-based emulsions on infection rate and leucocyte count in critically ill patients receiving parenteral nutrition. Br J Nutr. 2008;99(4):846–54.

7. Noor P, Yildiz BD, Yildiz EA, Besler T, Abbassoglu O. Olive oil-based fat emulsion versus soy oil-based fat emulsion in abdominal oncologic surgery. Nutr Clin Pract. 2011;26(1):55–5.

8. Palova S, Chavat J, Kypal M. Comparison of soybean oil- and olive oil-based lipid emulsions on hepatobiliary function and serum triacylglycerols level during realimentation. J Int Med Res. 2008;36(3):587–93.

9. Puigros C, Sanchez J, Chacon P, Sabin P, Rosello J, Bou R, et al. Evolution of lipid profile, liver function, and pattern of plasma fatty acids according to the type of lipid emulsion administered in parenteral nutrition in the early postoperative period after digestive surgery. JPEN J Parenter Enteral Nutr. 2009;33(5):501–12.

10. Vanek VW, Seidner DL, Allen P, Bistrian B, Collier S, Gura K, et al. A.S.P.E.N. position paper: clinical role for alternative intravenous fat emulsions. Nutr Clin Pract. 2012;27(2):150–92.

11. Cury-Boaventura MF, Gorjao R, de Lima TM, Fiamoncin J, Torres RP, Mancini-Filho J, et al. Effect of olive oil-based emulsion on human lymphocyte and neutrophil death. JPEN J Parenter Enteral Nutr. 2008;32(11):1817–7.

12. Furukawa K, Yamamoto H, Takagi K, Hayashi N, Suzuki R, Nakajima N, et al. Influences of soybean oil emulsion on stress response and cell-mediated immune function in moderately or severely stressed patients. Nutrition. 2002;18(3):235–40.

13. Okada Y, Klein NJ, van Saene HK, Webb G, Holzel H, Pierro A. Bacterial activity against coagulase-negative staphylococci is impaired in infants receiving long-term parenteral nutrition. Ann Surg. 2000;231(2):276–81.

14. Siqueira J, Smiley D, Newton C, Le GA, Gosmanov AR, Spiegelman et al. Substitution of standard soybean oil with olive oil-based lipid emulsion in parenteral nutrition: comparison of vascular, metabolic, and inflammatory effects. J Clin Endocrinol Metab. 2001;96(10):3207–16.

15. Garcia-de-Lorenzo A, Denia R, Atian P, Martinez-Rateau S, Le Brun A, Evard D, et al. Parenteral nutrition providing a restricted amount of linoleic acid in severely burned patients: a randomised double-blind study of an olive oil-based lipid emulsion vs. medium/long-chain triacylglycerols. Br J Nutr. 2005;94(6):221–30.

16. Yaoob P. Monounsaturated fats and immune function. Proc Nutr Soc. 1998;57(4):511–20.

17. Ingenbleek Y, Bernstein L. The stressful condition as a nutritionally dependent adaptive dichotomy. Nutrition. 1999;15(3):605–10.

18. Calder PC, Jensen GL, Koletzko BV, Singer P, Wanten GJ. Lipid emulsions in parenteral nutrition of intensive care patients: current thinking and future directions. Intensive Care Med. 2010;36(5):735–49.

19. Livingstone C. Insulin-like growth factor-1 (IGF-I) and clinical nutrition. Clin Sci (Lond). 2013;125(6):265–80.

20. Li ZZL, Wang WP, Hao CL, Guo K, Ma GW, Yu H, et al. Olive oil-based lipid emulsion for parental nutrition in patients after esophagectomy. Chinese Journal of Clinical Nutrition. 2011;19(4):74–81.